ALK and non-small cell lung carcinoma: Therefore, the combination of PI3Kβi and ALKi acts highly selectively on ALK‐rearranged NSCLC cells, while the combination of EGFRi and ALKi appears to act non‐specifically, also targeting the normal epithelial cells.